Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Ascletis Pharma, Inc. ( (HK:1672) ).
Ascletis Pharma Inc. has announced an increase in its share repurchase program from HK$300 million to HK$500 million, citing the undervaluation of its stock and significant recent achievements in drug development. The company aims to enhance shareholder value and demonstrate confidence in its long-term growth prospects, with the repurchase funded by internal resources and conducted in compliance with relevant regulations.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development of innovative drugs. The company specializes in oral small molecule therapies targeting metabolic and viral diseases, with a market focus on obesity, acne, and other conditions.
Average Trading Volume: 7,038,564
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.5B
See more insights into 1672 stock on TipRanks’ Stock Analysis page.